Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE®
- M. Hert, Bie Peuskens, R. Winkel, D. Kalnická, J. Peuskens
- Psychology, Medicine
- Schizophrenia Research
- 1 December 2006
BACKGROUND Metabolic abnormalities and weight gain are an important problem in patients with schizophrenia. An instrument to evaluate body image and self-esteem related to weight has recently been… Expand
Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.
- M. De Hert, D. Kalnická, +5 authors J. Peuskens
- The Journal of clinical psychiatry
- 1 December 2006
BACKGROUND Mortality rates in patients with schizophrenia are double compared to those in the general population, with cardiovascular disease causing 50% of the excess. Lowering low-density… Expand
Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia
- L. Hanssens, M. De Hert, +5 authors J. Peuskens
- International clinical psychopharmacology
- 1 January 2007
Mortality rates in patients with schizophrenia are double compared with the general population, with cardiovascular disease causing 50% of the excess. Lowering low-density lipoprotein cholesterol is… Expand
Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes.
- G. Kane, A. Stanson, +4 authors V. Garovic
- Nephrology, dialysis, transplantation : official…
- 8 January 2007
BACKGROUND Percutaneous angiography with iodinated contrast in patients with chronic kidney disease carries a risk of contrast nephropathy, which is independently associated with renal disease… Expand
Cognitive changes in spinocerebellar ataxia type 2.
OBJECTIVES Cognitive disorders and dementia occur in 19 to 42% of patients with spinocerebellar ataxia type 2 (SCA2). Neuropsychological tests can reveal executive dysfunction, impaired visual and… Expand
Prolactin as a factor for increased platelet aggregation.
- A. Urban, J. Masopust, R. Malý, L. Hosák, D. Kalnická
- Neuro endocrinology letters
- 1 August 2007
Administration of antipsychotics appears to be related to increased risk of venous thromboembolism and cerebrovascular side effects. The biological mechanism responsible for this possible adverse… Expand
Treatment with rosuvastatin for severe dyslipidaemia in patients with schizophrenia and Schizoaffective disorder
Case study Impulse control disorder associated with dopaminergic therapy in Parkinson’s disease - a case report
Cardiometabolic risk in patients with schizophrenia
Introduction Patients with schizophrenia have at least 20 years shorter life spam compared with general population that is primarily caused by their cardiovascular morbidity. Aims The aim of this… Expand
Assessment of microalbuminuria and ankle-brachial index in outpatients with schizophrenia treated with antipsychotics - a possible predictors of cardiovascular disease
Schizophrenia and related psychoses are associated with excess morbidity and mortality from cardiovascular (CV) disease. Microalbuminuria (MA) is associated with an increased risk of CV disease and… Expand